PDCD1 and neoplasm: Pembrolizumab, an anti-PD-1 antibody, has recently been demonstrated to be effective in a series of patients with advanced ENKTL, supporting the role of immune checkpoint molecules and immune evasion in the development of this aggressive tumor [11].